BCL2 and B-cell chronic lymphocytic leukemia: This approach can also be extended to test important CLL drugs, such as the BCL‐2 inhibitor venetoclax, the anti‐CD20 monoclonal antibody obinutuzumab, and BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib.